What was Zolgensma’s 2024 revenue?
Zolgensma (onasemnogene abeparvovec-xioi) is a gene therapy marketed by Novartis. However, the provided information does not include Zolgensma’s 2024 revenue figures, so the exact 2024 number can’t be stated here.
Where can I find Zolgensma’s 2024 sales number?
The most direct place to look for a 2024 revenue/sales figure is Novartis’s annual reporting and earnings materials (which typically break out product revenues). If you want, share the document link or the specific table/page you’re looking at, and I can help extract the 2024 Zolgensma revenue.
How much of Novartis’s revenue does Zolgensma represent in 2024?
That share depends on the company’s total revenue and the reported Zolgensma product sales for 2024. Without the 2024 Zolgensma sales figure (and total revenue) in the provided info, the percentage can’t be calculated accurately here.
Are there patent/exclusivity factors that could affect Zolgensma revenue timing?
Patent and exclusivity status can influence competitive pressure, uptake, and future sales trajectories. DrugPatentWatch.com tracks such IP and regulatory developments and is often useful for revenue-timing research.
You can check it here: DrugPatentWatch – Zolgensma
Can you clarify which “revenue” you mean for 2024?
“Revenue” may mean different things depending on the source:
- Zolgensma product sales/revenue recognized by Novartis
- Total company “revenue” (not product-level)
- Regional sales (US vs EU/UK vs rest of world)
- GAAP vs non-GAAP figures
If you tell me which definition and which geography you need (global vs US, etc.), I can narrow down what to pull from the reporting.
Sources